PulseSight Therapeutics to Present PST-611 Data for Dry AMD at EVER Congress 2024
核心洞察
PulseSight Therapeutics (搜索) will present data on PST-611, a non-viral vectorized gene therapy expressing human transferrin (搜索), for dry age-related macular degeneration (搜索) (AMD) at the EVER Congress.
PST-611 aims to restore iron homeostasis in retinal cells, mitigating oxidative stress and inflammation associated with geographic atrophy (搜索) (GA).
The company plans to submit a Phase I clinical trial authorization by the end of October 2024, followed by a Phase II proof-of-concept study by end of 2027.
PulseSight Therapeutics (搜索) SAS is set to present data on its lead program, PST-611, for dry age-related macular degeneration (搜索) (AMD) and geographic atrophy (搜索) (GA) at the European Association for Vision and Eye Research (EVER) 27th Congress in Valencia, Spain, from November 3-5, 2024. The company will deliver an oral presentation and a poster presentation detailing the potential of PST-611, which expresses human transferrin (搜索), in treating this debilitating condition.
PST-611: A Novel Approach to Dry AMD Treatment
PST-611 is a DNA plasmid encoding human transferrin (搜索), a potent iron chelator. Excess iron in retinal cells is known to cause oxidative stress, inflammation, and ferroptosis, contributing to the progression of GA. By restoring normal iron homeostasis, PST-611 aims to protect retinal cells and slow the growth of GA lesions, potentially improving visual function in patients.
Thierry Bordet, CSO of PulseSight Therapeutics (搜索), highlighted the significance of the presentation at the EVER Congress, stating, "EVER attracts top European researchers and the most innovative industry players, and I am delighted that we have been accepted to present our recent promising data on PST-611, our pioneering, first-in-class non-viral vectorized gene therapy for the treatment of dry AMD/GA."
Upcoming Clinical Trials and Safety Profile
PulseSight Therapeutics (搜索) is planning to submit a Phase I clinical trial authorization (CTA) by the end of October 2024. This will be followed by a Phase II proof-of-concept study to evaluate the efficacy and safety of PST-611, with results expected by the end of 2027. The company emphasizes the favorable safety profile of PST-611, which is supported by safety data from a previous clinical trial involving PST-606 (搜索) in uveitis (搜索), as noted by Karine Bigot, Head of Pharmacology & Toxicology at PulseSight Therapeutics.
Addressing Unmet Needs in AMD Treatment
Age-related macular degeneration (搜索) (AMD) is a progressive disease leading to irreversible vision loss in the elderly. Dry AMD, which can evolve into geographic atrophy (搜索) (GA), represents a significant unmet need for more effective and durable treatment options. The market for AMD treatments is projected to reach $27.5 billion by 2031, underscoring the importance of innovative therapies like PST-611.
Presentations at EVER Congress
The presentations at the EVER Congress will include:
- Oral Presentation by Dr. Thierry Bordet (CSO): Transferrin is a drug candidate for the treatment of geographic atrophy (GA)/dry age-related macular degeneration (AMD). November 5, 2024, 9:20 am - 10:35 am CET.
- Poster Presentation by Dr. Karine Bigot (Head Pharmacology & Toxicology): Non-clinical safety of PST-611, non-viral vectorized human transferrin, for the treatment of geographic atrophy (GA). November 5, 2024, 11:05 am - 12:05 pm CET.